Wells Fargo Upgrades Viridian Therapeutics to Overweight, Raises Price Target to $31
Benzinga Newsdesk 4 months ago
NewsUpgradesAnalyst RatingsPrice Target
Wells Fargo analyst Derek Archila upgrades Viridian Therapeutics (NASDAQ:VRDN) from Equal-Weight to Overweight and raises the price target from $20 to $31.
Wells Fargo analyst Derek Archila upgrades Viridian Therapeutics (NASDAQ:VRDN) from Equal-Weight to Overweight and raises the price target from $20 to $31.